E.W. Scripps Completes Sale of San Diego Tower Sites for $20 Million to K2 Towers-February 2024-www.financetom.com

E.W. Scripps Completes Sale of San Diego Tower Sites for $20 Million to K2 Towers

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

E.W. Scripps Completes Sale of San Diego Tower Sites for $20 Million to K2 Towers

Jan 3, 2025 11:26 AM

02:12 PM EST, 01/03/2025 (MT Newswires) -- E.W. Scripps (SSP) completed the sale of tower sites in San Diego to K2 Towers for $20 million in cash.

Tower space leases were signed with the buyer for $1 million annually, Scripps said Friday in a regulatory filing.

Price: 2.51, Change: -0.02, Percent Change: -0.60

Previous page： --Street Color: Boeing Faces New Airworthiness Guidelines From US Federal Aviation Administration for 787 Models Next page： Icahn, firm settle US SEC charges over alleged disclosure failures

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Street Color: Boeing Faces New Airworthiness Guidelines From US Federal Aviation Administration for 787 Models

Aug 19, 2024

09:18 AM EDT, 08/19/2024 (MT Newswires) -- Price: 180.40, Change: +0.41, Percent Change: +0.23 ...

Icahn, firm settle US SEC charges over alleged disclosure failures

Aug 19, 2024

(Reuters) -Billionaire investor Carl Icahn and his firm Icahn Enterprises LP (IEP) have settled charges for failing to disclose pledges of the company's securities as collateral for billions of dollars in personal loans, U.S. regulators said on Monday. The firm and Icahn agreed to pay $1.5 million and $500,000 in civil penalties, respectively, to settle the charges, the U.S. Securities...

Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia

Aug 19, 2024

09:19 AM EDT, 08/19/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Monday said Australia's Human Research Ethics Committee (HREC) has approved the company's Phase 1 clinical trial of SAT-3247, its lead candidate which is being advanced as a potential treatment for Duchenne muscular dystrophy (DMD). The Phase 1 trial will have two components. In the first, 72 healthy...

What's Going On With Theriva Biologics (TOVX) Stock?

Aug 19, 2024

Theriva Biologics Inc ( TOVX ) shares are trading lower by 15% to $0.17 Monday morning after the company announced a 1-for-25 reverse stock split. This reverse stock split will become effective on August 26. The company’s common stock will begin trading on a split-adjusted basis when the market opens on that day. The reverse stock split was authorized by...